Aspira Women's Health Inc.

Equities

AWH

US04537Y2081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 04/06/2024 am IST			5-day change	1st Jan Change
2.51 ^USD	+1.62%		+13.06%	-38.48%

15/05	Transcript : Aspira Women's Health Inc., Q1 2024 Earnings Call, May 15, 2024
15/05	Earnings Flash (AWH) ASPIRA WOMEN'S HEALTH Reports Q1 Revenue $2.2M, vs. Street Est of $2.6M	MT

Aspira Women?S Health Inc. Announces Resignation of Ryan Phan as Chief Scientific and Operating Officer, Effective September 15, 2023

August 10, 2023 at 01:35 am IST

Aspira Women?s Health Inc. announced that Ryan Phan, Ph.D., is stepping down as the Company?s Chief Scientific and Operating Officer effective September 15, 2023. Dr. Phan is expected to remain as an advisor for the Company to provide scientific and operational advice related to ongoing product development programs.

Latest news about Aspira Women's Health Inc.

Transcript : Aspira Women's Health Inc., Q1 2024 Earnings Call, May 15, 2024	15/05
Earnings Flash (AWH) ASPIRA WOMEN'S HEALTH Reports Q1 Revenue $2.2M, vs. Street Est of $2.6M	15/05	MT
Aspira Women's Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Aspira Women's Health Inc. Enhances Its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of Ovawatch	02/05	CI
Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024	27/04	CI
Cantor Fitzgerald Trims Price Target on Aspira Women's Health to $3.30 From $4, Maintains Neutral Rating	01/04	MT
Transcript : Aspira Women's Health Inc., Q4 2023 Earnings Call, Mar 28, 2024	28/03
Earnings Flash (AWH) ASPIRA WOMEN'S HEALTH Posts Q4 Revenue $2.1M	28/03	MT
Aspira Women's Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Aspira Women's Health Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03	CI
Aspira Women's Health Inc. Announces Executive Changes	18/03	CI
Aspira Women's Health Inc. Announces OvaSuite(SM) Distribution Agreement in the Philippines	06/02	CI
Aspira Women's Health Inc. announced that it expects to receive $5.5 million in funding	24/01	CI
Transcript : Aspira Women's Health Inc. - Special Call	04/01
Aspira Women's Health Inc. Announces Resignation of Veronica G.H. Jordan from the Board of Directors	28/12	CI
Aspira Women's Health Provides Development Update on its Portfolio of Noninvasive Tests for Endometriosis	06/12	CI
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services	27/11	CI
Transcript : Aspira Women's Health Inc., Q3 2023 Earnings Call, Nov 13, 2023	14/11
Earnings Flash (AWH) ASPIRA WOMEN'S HEALTH Posts Q3 Revenue $2.2M, vs. Street Est of $2.9M	14/11	MT
Aspira Women's Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Aspira Women's Health Sees Poster on its MiRNA-Based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research	25/23/25	CI
Aspira Women's Health Establishes A New Clinical Advisory Board	23/23/23	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	14/23/14	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	13/23/13	MT
Top Midday Gainers	13/23/13	MT

Chart Aspira Women's Health Inc.

Duration

Period

More charts

Company Profile

Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Aspira Women's Health Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.47 USD

Average target price

5.25 USD

Spread / Average Target

+112.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
ASPIRA WOMEN'S HEALTH INC.	-38.48%	3.05Cr
EXACT SCIENCES CORPORATION	-39.42%	838.69Cr
GUARDANT HEALTH, INC.	+1.33%	331.62Cr
IOVANCE BIOTHERAPEUTICS, INC.	+2.95%	248.49Cr
BGI GENOMICS CO., LTD.	-19.81%	205.7Cr
VERACYTE, INC.	-23.12%	158.63Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	+33.59%	115.16Cr
SEEGENE, INC.	-7.21%	70Cr
CAREDX, INC	+11.33%	68Cr
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-32.45%	51Cr

Bio Diagnostics & Testing